Adalimumab in ulcerative colitis: Ready for prime time

Digestive and Liver Disease

Volumn 45, Issue 1, 2013, Pages 8-13

  Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Anti TNF ; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

COLON MUCOSA; COLON RESECTION; CORTICOSTEROID THERAPY; DELAYED HYPERSENSITIVITY; DERMATITIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MYCOSIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REMISSION; REVIEW; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; HUMANS; TREATMENT OUTCOME;

EID: 84871613859     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.05.021     Document Type: Review

References (47)

1. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
2. Danese S. What's hot in inflammatory bowel disease in 2011?. World Journal of Gastroenterology 2011, 17:545-546.
3. Danese S., Angelucci E., Malesci A., et al. Biological agents for ulcerative colitis: hypes and hopes. Medicinal Research Reviews 2008, 28:201-218.
4. Danese S., Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011, 365:1713-1725.
5. Carter M.J., Lobo A.J., Travis S.P. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004, 53(Suppl. 5):V1-V16.
6. Rubin D.T., Siegel C.A., Kane S.V., et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflammatory Bowel Diseases 2009, 15:581-588.
7. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
8. Gies N., Kroeker K.I., Wong K., et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Alimentary Pharmacology and Therapeutics 2010, 32:522-528.
9. Umanskiy K., Fichera A. Health related quality of life in inflammatory bowel disease: the impact of surgical therapy. World Journal of Gastroenterology 2010, 16:5024-5034.
10. Danese S. Ulcerative colitis: a cinderella story. Current Drug Targets 2011, 12:1372.
11. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61(6):918-932.
12. Fiorino G., Peyrin-Biroulet L., Repici A., et al. Adalimumab in ulcerative colitis: hypes and hopes. Expert Opinion on Biological Therapy 2011, 11:109-116.
13. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012.
14. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 2000, 355:735-740.
15. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis 2010, 4:355-366.
16. Danese S., Colombel J.F., Reinisch W., et al. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Alimentary Pharmacology and Therapeutics 2011, 33:857-869.
17. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. American Journal of Gastroenterology 2009, 104:760-767.
18. Use EMACfMPfH. Humira - Summary of opinion; 2012. Available from: [20.05.12]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000481/smops/Positive/human_smop_000341.jsp%26mid=WC0b01ac058001d127%26jsenabled=true.
19. Actis G.C., Bruno M., Pinna-Pintor M., et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Digestive and Liver Disease 2002, 34:631-634.
20. Chey W.Y. Infliximab for patients with refractory ulcerative colitis. Inflammatory Bowel Diseases 2001, 7(Suppl. 1):S30-S33.
21. Daperno M., Sostegni R., Scaglione N., et al. Outcome of a conservative approach in severe ulcerative colitis. Digestive and Liver Disease 2004, 36:21-28.
22. Gornet J.M., Couve S., Hassani Z., et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Alimentary Pharmacology and Therapeutics 2003, 18:175-181.
23. Kohn A., Prantera C., Pera A., et al. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. European Review for Medical and Pharmacological Sciences 2004, 8:235-237.
24. Ochsenkuhn T., Sackmann M., Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology and Hepatology 2004, 16:1167-1171.
25. Probert C.S., Hearing S.D., Schreiber S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998-1002.
26. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflammatory Bowel Diseases 2001, 7:83-88.
27. Su C., Salzberg B.A., Lewis J.D., et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. American Journal of Gastroenterology 2002, 97:2577-2584.
28. Oussalah A., Laclotte C., Chevaux J.B., et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Alimentary Pharmacology and Therapeutics 2008, 28:966-972.
29. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265. e1-3.
30. Peyrin-Biroulet L., Laclotte C., Roblin X., et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World Journal of Gastroenterology 2007, 13:2328-2332.
31. Afif W., Leighton J.A., Hanauer S.B., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflammatory Bowel Diseases 2009, 15:1302-1307.
32. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
33. Reinisch W, Sandborn WJ, Hommes DW, et al. Effect of ADALIMUMAB induction therapy on clinical laboratory parameters suggesting improved nutrition and inflammation status in patients with moderately to severely active ulcerative colitis. 2010 Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology (ACG), San Antonio, TX, USA; 2010.
34. Konstantopoulos P., Papamichael K., Archavlis E., et al. Long term effect of anti-TNFa agents on the lipidemic profile of IBD patients. 7th congress of the European Crohn's and Colitis Organisation (ECCO) 2012.
35. Reinisch W., Sandborn W.J., Kumar A., et al. 52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Gut 2011, 60(Suppl. 1):A139-A140.
36. Feagan B., Sandborn W.J., Yang M., et al. Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis: data from controlled trials. 2011 annual scientific meeting and postgraduate course of the American College of Gastroenterology (ACG) 2011.
37. Garcia-Bosch O, Aceituno M, Gisbert JP, et al. Efficacy of adalimumab in the treatment of ulcerative colitis. Digestive Disease Week 2010 (DDW), New Orleans, LA, USA; 2010.
38. Taxonera C., Estelles J., Fernandez-Blanco I., et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology and Therapeutics 2011, 33:340-348.
39. Armuzzi A., Biancone L., Daperno M., et al. Adalimumab in active ulcerative colitis: A real-life observational study. 7th congress of the European Crohn's and Colitis Organisation (ECCO) 2012.
40. Hudis N, Rajca, Polyak S, et al. The outcome of active ulcerative colitis treated with adalimumab. Digestive Disease Week 2009 (DDW), Chicago, IL, USA; 2009.
41. Singh A., Mahadevan U., Yen E., et al. Adalimumab for patients with ulcerative colitis who have lost response or are intolerant of infliximab: initial response rates are high, but the response may not be durable. 2009 annual scientific meeting of the American College of Gastroenterology (ACG) 2009.
42. Trinder M.W., Lawrance I.C. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. Journal of Gastroenterology and Hepatology 2009, 24:1252-1257.
43. Molander P., Af Bjorkesten C.G., Mustonen H., et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflammatory Bowel Diseases 2012.
44. Colombel J.F., Sandborn W.J., Panaccione R., et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflammatory Bowel Diseases 2009, 15:1308-1319.
45. Sandborn W.J., Van Assche G., Thakkar R., et al. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis. 2012 annual meeting of the Canadian Association of Gastroenterology (CAG) held jointly with the Canadian Association for the Study of the Liver (CASL): Canadian Digestive Disease Week (CDDW) 2012.
46. Feagan B., Gunnarsson C., Mallow P., et al. Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis. 2012 annual meeting of the Canadian Association of Gastroenterology (CAG) held jointly with the Canadian Association for the Study of the Liver (CASL): Canadian Digestive Disease Week (CDDW) 2012.
47. Barreiro-de Acosta M., Lorenzo A., Dominguez-Munoz J.E. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World Journal of Gastroenterology 2009, 15:3814-3816.